2012-77-3 Usage
General Description
2-(2,3-Dichlorophenyl)propionic acid is a chemical compound with anti-inflammatory properties. It is commonly used as a nonsteroidal anti-inflammatory drug (NSAID) and is used to relieve pain and reduce inflammation in conditions such as arthritis and musculoskeletal disorders. It works by inhibiting the production of prostaglandins, which are substances in the body that cause pain and inflammation. This chemical is typically taken orally and is available in various forms, including tablets and capsules. It is important to use this medication as directed by a healthcare professional, as it can have potential side effects and interactions with other medications.
Check Digit Verification of cas no
The CAS Registry Mumber 2012-77-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,0,1 and 2 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 2012-77:
(6*2)+(5*0)+(4*1)+(3*2)+(2*7)+(1*7)=43
43 % 10 = 3
So 2012-77-3 is a valid CAS Registry Number.
InChI:InChI=1/C9H8Cl2O2/c1-5(9(12)13)6-3-2-4-7(10)8(6)11/h2-5H,1H3,(H,12,13)
2012-77-3Relevant articles and documents
2-(Halogenated Phenyl) acetamides and propanamides as potent TRPV1 antagonists
Ann, Jihyae,Bahrenberg, Gregor,Blumberg, Peter M.,Choi, Sun,Christoph, Thomas,Do, Nayeon,Frank-Foltyn, Robert,Ha, Heejin,Jeong, Jin Ju,Kang, Jin Mi,Kim, Changhoon,Kwon, Sun Ok,Lee, Jeewoo,Lee, Sunho,Lesch, Bernhard,Stockhausen, Hannelore,Vu, Thi Ngoc Lan,Yoon, Sanghee
, (2021/07/28)
A series consisting of 117 2-(halogenated phenyl) acetamide and propanamide analogs were investigated as TRPV1 antagonists. The structure–activity analysis targeting their three pharmacophoric regions indicated that halogenated phenyl A-region analogs exhibited a broad functional profile ranging from agonism to antagonism. Among the compounds, antagonists 28 and 92 exhibited potent antagonism toward capsaicin for hTRPV1 with Ki[CAP] = 2.6 and 6.9 nM, respectively. Further, antagonist 92 displayed promising analgesic activity in vivo in both phases of the formalin mouse pain model. A molecular modeling study of 92 indicated that the two fluoro groups in the A-region made hydrophobic interactions with the receptor.
